, /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd.
(Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in , will announce findings from an updated systematic literature review (SLR) and meta-analysis comparing the safety of NOURIANZ (istradefylline) in relation to other levodopa adjunctive therapies for patients with Parkinson's Disease (PD). NOURIANZ is an adenosine receptor antagonist used with levodopa/carbidopa to treat adults with PD experiencing "off" episodes, the return of Parkinson's symptoms between medication doses. The findings will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, during a poster presentation on , from 5:30 – .
Parkinson's disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement, and postural instability. Within 5 years of starting levodopa/carbidopa treatment, half of people living with PD begin to experience "off" time, including problems with movement. Adjunctive therapies may be used to treat these episodes but are often hampered by safety and tolerability issues that limit their clinical utility.
"With the growing landscape of adjunctive therapies for Parkinson's disease, it is important for physicians to have data that demonstrates the relative risk profiles of these treatment options," said lead author , MD, MedStar Hospital. "These data provide useful information on safety and tolerability of these.